期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

国产伊马替尼治疗初发慢性髓性白血病的疗效与安全性观察 被引量：9

Efficacy and safety of generic imatinib mesylate capsules produced in China for newly diagnosed chronic myeloid leukemia in chronic phase patients
原文传递
导出
摘要 伊马替尼是第一代酪氨酸激酶抑制剂（TKI）,能特异性阻断BCR-ABL激酶的磷酸化,极大地改善了慢性髓性白血病（CML）患者的预后[1].针对干扰素和伊马替尼的国际随机调查研究（IRIS）结果显示,接受瑞士诺华公司生产甲磺酸伊马替尼（商品名格列卫）治疗的CML-慢性期（CP）患者预期8年生存率为85％,如果只考虑CML相关死亡,其预期8年生存率高达93％[2].尽管格列卫治疗CML的远期疗效显著,但由于费用昂贵,大多数中国患者难以承受.
作者 陈娟 周励 杜圣红 卢虹颖 孙舒君 李军民 赵维莅 沈志祥
机构地区 上海交通大学医学院附属瑞金医院血液科
出处 《中华血液学杂志》 CAS CSCD 北大核心 2015年第3期235-237,共3页 Chinese Journal of Hematology
关键词 甲磺酸伊马替尼 慢性髓性白血病 远期疗效 安全性观察 治疗 酪氨酸激酶抑制剂 BCR-ABL 初发
分类号 R733.72 [医药卫生—肿瘤]
  • 相关文献

参考文献2

二级参考文献6

  • 1Sneed TB, Kantarjian HM, Talpaz M, et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer, 2004, 100:116-121.
  • 2Buchdunger E, Matter A, Druker BJ. Bcr-Abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta, 2001, 1551 : M11-18.
  • 3Socal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good risk" chronic granulocytic leukemia. Blood, 1984, 63 : 789 -799.
  • 4O' Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med, 2003, 348 : 994-1004.
  • 5Droker BJ, O' Brien SG, Guilhot F, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 2006, 355:2408-2417.
  • 6Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of phase 2 study. Blood, 2002, 99 : 1928-1937.

共引文献55

同被引文献48

  • 1李珍,马思聪,周红升,蒋玲.伊马替尼治疗慢性嗜酸性粒细胞白血病合并中枢侵犯1例并文献复习[J].内科急危重症杂志,2020,0(1):77-79. 被引量：1
  • 2江倩,陈珊珊,江滨,江浩,丘镜滢,刘艳荣,张艳,秦亚溱,陆颖,黄晓军,陆道培.甲磺酸伊马替尼治疗慢性粒细胞白血病慢性期100例追踪观察[J].中华血液学杂志,2006,27(11):721-726. 被引量：39
  • 3Deninger MO,Brien SG,Guilhot F,et al.International randomized study of interferon vs STl571(IRIS)8-year follow up sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic-phase(CML-CP)treated with imatinib[J].Blood,2009,114:462.
  • 4Wang AH,Wang YY,Yao Y,et al.Summary of 615patients of chronic myeloid leukemia in Shanghai from2001to 2006[J].J Exp Clin Cancer Res,2010,29:20.
  • 5NCCN clinical practice guide lines in oncology(NCCN guidelines):chronic myelogenous leukemia[S/OL].Version I.2015[2014-08-28].
  • 6Baccarani M,Deininger MW,Rosti G,et al.European LeukemiaNet recommendations for the management of chronic myeloid leukemia:2013[J].Blood,2013,122:872-884.
  • 7Kim DD,Hamad N,Lee HG,et al.BCR/ABL level at6 months identifies good risk CML subgroup after failing early molecular response at 3months following imatinib therapy for CML in chronic phase[J].Am J Hematol,2014,89:626-632.
  • 8Jabbour E,Kanta6ian HM,Saglio G,et al.Early response with dasatinib or imatinib in chronic myeloid leukemia:3-year follow-up from a randomized phase 3trial(DASISION)[J].Blood,2014,123:494-500.
  • 9Ferlay J,Soerjomataram I,Ervik M,et al. GLOBOCAN 2012 vl.0,cancer incidence and mortality worldwide: IARC CancerBase No.ll[EB/OL]. http://globocan, iarc.fr,2014.
  • 10Cui C,Mao L,Chi Z,et al. A phase' [[ ,randomized,dou- ble-blind,placebo-controlled muhicenter trial of Endostar in patients with metastatic melanoma [J]. Mol Ther, 2013,21(7) : 1456-1463.

引证文献9

二级引证文献34

中华血液学杂志
2015年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部